BlackRock’s Ligand Pharmaceuticals LGND Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$591M Buy
2,961,923
+21,692
+0.7% +$4.29M 0.01% 978
2025
Q4
$556M Buy
2,940,231
+55,704
+2% +$10.7M 0.01% 1023
2025
Q3
$511M Sell
2,884,527
-29,214
-1% -$4.34M 0.01% 1071
2025
Q2
$331M Sell
2,913,741
-6,494
-0.2% -$694K 0.01% 1303
2025
Q1
$307M Sell
2,920,235
-25,849
-0.9% -$2.92M 0.01% 1329
2024
Q4
$316M Sell
2,946,084
-53,548
-2% -$6.05M 0.01% 1397
2024
Q3
$300M Buy
2,999,632
+128,136
+4% +$12.9M 0.01% 1417
2024
Q2
$242M Buy
2,871,496
+3,226
+0.1% +$257K 0.01% 1497
2024
Q1
$210M Sell
2,868,270
-94,044
-3% -$6.93M ﹤0.01% 1611
2023
Q4
$212M Buy
2,962,314
+121,230
+4% +$7.15M 0.01% 1617
2023
Q3
$170M Sell
2,841,084
-65,075
-2% -$4.28M ﹤0.01% 1649
2023
Q2
$210M Buy
2,906,159
+67,497
+2% +$5.06M 0.01% 1542
2023
Q1
$209M Buy
2,838,662
+48,898
+2% +$3.48M 0.01% 1502
2022
Q4
$186M Sell
2,789,764
-1,483,222
-35% -$96.4M 0.01% 1590
2022
Q3
$230M Sell
4,272,986
-62,884
-1% -$3.7M 0.01% 1365
2022
Q2
$241M Sell
4,335,870
-45,621
-1% -$2.59M 0.01% 1383
2022
Q1
$307M Sell
4,381,491
-15,230
-0.3% -$1.11M 0.01% 1342
2021
Q4
$424M Buy
4,396,721
+18,617
+0.4% +$1.72M 0.01% 1162
2021
Q3
$381M Buy
4,378,104
+1,100,966
+34% +$85.2M 0.01% 1210
2021
Q2
$268M Sell
3,277,138
-131,454
-4% -$10.9M 0.01% 1551
2021
Q1
$324M Buy
3,408,592
+257,100
+8% +$24.3M 0.01% 1367
2020
Q4
$196M Sell
3,151,492
-272,692
-8% -$15.5M 0.01% 1636
2020
Q3
$204M Buy
3,424,184
+13,553
+0.4% +$925K 0.01% 1375
2020
Q2
$238M Sell
3,410,631
-129,652
-4% -$8.22M 0.01% 1236
2020
Q1
$161M Sell
3,540,283
-283,125
-7% -$16M 0.01% 1325
2019
Q4
$249M Sell
3,823,408
-118,218
-3% -$7.9M 0.01% 1318
2019
Q3
$245M Sell
3,941,626
-64,119
-2% -$4.03M 0.01% 1256
2019
Q2
$285M Sell
4,005,745
-385,281
-9% -$28.4M 0.01% 1159
2019
Q1
$344M Sell
4,391,026
-36,237
-0.8% -$2.75M 0.02% 1009
2018
Q4
$375M Sell
4,427,263
-937,026
-17% -$99.9M 0.02% 825
2018
Q3
$919M Buy
5,364,289
+130,536
+2% +$19.7M 0.04% 454
2018
Q2
$676M Buy
5,233,753
+402,585
+8% +$44.9M 0.03% 556
2018
Q1
$498M Buy
4,831,168
+27,041
+0.6% +$2.67M 0.02% 708
2017
Q4
$410M Buy
4,804,127
+82,168
+2% +$7.12M 0.02% 825
2017
Q3
$401M Buy
4,721,959
+419,699
+10% +$33.2M 0.02% 801
2017
Q2
$326M Buy
4,302,260
+110,426
+3% +$7.72M 0.02% 926
2017
Q1
$277M Buy
4,191,834
+4,189,319
+166,573% +$276M 0.02% 1036
2016
Q4
$159K Sell
2,515
-576
-19% -$36.3K ﹤0.01% 2286
2016
Q3
$197K Sell
3,091
-4,603
-60% -$338K ﹤0.01% 2162
2016
Q2
$572K Buy
7,694
+5,480
+248% +$407K ﹤0.01% 1623
2016
Q1
$147K Buy
2,214
+1,379
+165% +$83.8K ﹤0.01% 1823
2015
Q4
$56K Sell
835
-255
-23% -$15.7K ﹤0.01% 1988
2015
Q3
$59K Sell
1,090
-9,604
-90% -$583K ﹤0.01% 1842
2015
Q2
$673K Buy
10,694
+9,607
+884% +$524K ﹤0.01% 1477
2015
Q1
$52K Sell
1,087
-1,055
-49% -$40.4K ﹤0.01% 1936
2014
Q4
$71K Buy
2,142
+1,267
+145% +$41.2K ﹤0.01% 1825
2014
Q3
$26K Hold
875
﹤0.01% 2200
2014
Q2
$34K Sell
875
-133
-13% -$5.4K ﹤0.01% 2107
2014
Q1
$43K Buy
1,008
+304
+43% +$12.7K ﹤0.01% 1978
2013
Q4
$23K Sell
704
-46
-6% -$1.5K ﹤0.01% 2293
2013
Q3
$20K Hold
750
﹤0.01% 2276
2013
Q2
$18K Buy
+750
New +$13.5K ﹤0.01% 2350

Other funds holding LGND

BlackRock's LGND Position: Q1 2026 in Review

BlackRock increased its Ligand Pharmaceuticals (LGND) stake by 0.74% in Q1 2026, buying an estimated $4.29M and bringing the position to 2,961,923 shares worth $591M. The position accounts for 0.01% of the portfolio, ranked #978.

BlackRock first reported a position in LGND in Q2 2013 and has held it in 52 quarters since. The position peaked at $919M in Q3 2018. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • BlackRock held 2,961,923 shares of Ligand Pharmaceuticals worth $591M as of Q1 2026.
  • BlackRock bought 21,692 Ligand Pharmaceuticals shares in Q1 2026, an estimated $4.29M.
  • Ligand Pharmaceuticals made up 0.01% of BlackRock's portfolio in Q1 2026, its #978 holding.
  • BlackRock first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • BlackRock's Ligand Pharmaceuticals position peaked at $919M in Q3 2018.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.